---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-24-000148"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2024-09-03T23:59:59+00:00"
generated_at: "2026-05-31T06:37:40.824031+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "medium"
source: SEC EDGAR
---

# Recursion reports top-line SYCAMORE data, files Exscientia financials for proposed merger

## Summary
- SYCAMORE Phase 2 trial for REC-994 in symptomatic CCM patients: top-line results announced Sept 3, 2024 (press release as Exhibit 99.2).
- Filed audited financials of Exscientia for FY2023 and FY2022 (Exhibit 99.3) and unaudited interim statements for H1 2024 (Exhibit 99.4).
- Filed pro forma condensed combined balance sheet as of June 30, 2024 and pro forma statements of operations (Exhibit 99.5).
- Transaction closing deadline Aug 8, 2025; termination fees: Recursion $58.77M, Exscientia $6.88M; subject to HSR, court, stockholder votes.

## SEC filing metadata
- accession: 0001601830-24-000148
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2024-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: medium
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000148/0001601830-24-000148-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000148/rxrx-20240903.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-24-000148
- JSON: https://secwatch.observer/filing/0001601830-24-000148.json
- Plain text: https://secwatch.observer/filing/0001601830-24-000148.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.